CD274 and neoplasm: In conclusion, this study demonstrated that bispecific antibody Y111, targeting the CD3 on Vγ2Vδ2 T cells and the PD-L1 on the tumor cells, could harness the anti-tumor potential of the Vγ2Vδ2 T cells to kill the cancer cells in vitro and inhibit the growth of the established xenograft tumors in vivo.